VP1-03 Unlocking Preclinical Drug Screening Application with Magnetoimpedance Sensor
Creators: Jiaju Ma
Norikazu Ohta
Takashi Ozaki
Shinya Moribe
Hirokazu Kikuta
Yusuke Hirata and Minoru Hirano
Publisher: name: IEEE
Year: 2025

In vitro cardiac function assays for drug screening have traditionally relied on electrophysiological techniques like the patch-clamp method and microelectrode arrays (MEA), as well as fluorescent microscopy. However, these methods often induce cellular stress and damage, require skilled operators, and necessitate specialized culture dishes [1, 2]. To address these limitations, we have developed a non-invasive, real-time magnetic recording system utilizing Magneto-Impedance (MI) sensors. Our system improves the sensor detection methodologies, and incorporates noise reduction techniques to enhance sensitivity and simplify drug screening. It boasts high field detection sensitivity, excellent linearity, and a noise level of approximately 2 pT/Hz1/2 at room temperature. As shown in Figure 1, we have successfully performed the first measurement and analysis of magnetophysiological signals from human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) using MI sensors. We compared our results with those obtained from existing techniques such as MEA and fluorescence imaging. Our MI sensor detected signals featuring a sharp peak combined with low-frequency components (Fig. 1(c)). Our system effectively assesses the impact of drugs with positive chronotropic properties and those that may induce serious side effects, such as QT prolongation, at therapeutic blood concentration levels. Fig. 2 illustrates the beat rate of hiPSC-CMs measured by the MI sensor, both with and without treatment using positive and negative reagents. The observed trends matched those obtained with two other measurement methods [3]. Using our system, we propose the potential for high-throughput, preclinical drug screening assays with magnetic detection. This technique obviates the need for expensive, bulky equipment or specialized culturing instruments, thus overcoming previous challenges in the field.References: [1] O. Scheel, S. Frech, B. Amuzescu, et al., ASSAY and Drug Development Technologies, 12, 457-469 (2014). [2] M.F. Peters, S.D. Lamore, L. Guo, et al., Cardiovasc Toxicol, 15 127-139 (2015). [3] L. Guo, R.M.C. Abrams, J.E. Babiarz, et al., TOXICOLOGICAL SCIENCES 123(1), 281–289 (2011)
In vitro cardiac function assays for drug screening have traditionally relied on electrophysiological techniques like the patch-clamp method and microelectrode arrays (MEA), as well as fluorescent microscopy. However, these methods often induce cellular stress and damage, require skilled operators, and necessitate specialized culture dishes [1, 2]. To address these limitations, we have developed a non-invasive, real-time magnetic recording system utilizing Magneto-Impedance (MI) sensors. Our system improves the sensor detection methodologies, and incorporates noise reduction techniques to enhance sensitivity and simplify drug screening. It boasts high field detection sensitivity, excellent linearity, and a noise level of approximately 2 pT/Hz1/2 at room temperature. As shown in Figure 1, we have successfully performed the first measurement and analysis of magnetophysiological signals from human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) using MI sensors. We compared our results with those obtained from existing techniques such as MEA and fluorescence imaging. Our MI sensor detected signals featuring a sharp peak combined with low-frequency components (Fig. 1(c)). Our system effectively assesses the impact of drugs with positive chronotropic properties and those that may induce serious side effects, such as QT prolongation, at therapeutic blood concentration levels. Fig. 2 illustrates the beat rate of hiPSC-CMs measured by the MI sensor, both with and without treatment using positive and negative reagents. The observed trends matched those obtained with two other measurement methods [3]. Using our system, we propose the potential for high-throughput, preclinical drug screening assays with magnetic detection. This technique obviates the need for expensive, bulky equipment or specialized culturing instruments, thus overcoming previous challenges in the field.References: [1] O. Scheel, S. Frech, B. Amuzescu, et al., ASSAY and Drug Development Technologies, 12, 457-469 (2014). [2] M.F. Peters, S.D. Lamore, L. Guo, et al., Cardiovasc Toxicol, 15 127-139 (2015). [3] L. Guo, R.M.C. Abrams, J.E. Babiarz, et al., TOXICOLOGICAL SCIENCES 123(1), 281–289 (2011)